Amicus Therapeutics, Inc. (NASDAQ:FOLD) is scheduled to release its earnings data before the market opens on Monday, November 6th. Analysts expect Amicus Therapeutics to post earnings of ($0.37) per share for the quarter.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same period in the prior year, the business earned ($0.40) earnings per share. On average, analysts expect Amicus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $14.43 on Friday. The company has a quick ratio of 2.35, a current ratio of 2.39 and a debt-to-equity ratio of 0.60.

Several brokerages recently commented on FOLD. BidaskClub cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Chardan Capital raised their target price on Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Robert W. Baird raised their target price on Amicus Therapeutics from $12.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 12th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.81.

ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics, Inc. (FOLD) Scheduled to Post Earnings on Monday” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/05/amicus-therapeutics-inc-fold-scheduled-to-post-earnings-on-monday.html.

In other news, insider Hung Do sold 50,194 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $715,264.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Daphne Quimi sold 7,000 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $99,750.00. The disclosure for this sale can be found here. Insiders have sold 628,224 shares of company stock valued at $9,024,003 over the last quarter. Corporate insiders own 3.40% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.